IAP antagonists induce anti-tumor immunity in multiple myeloma
| Autor: | Yan W. Asmann, Craig B. Reeder, P. Leif Bergsagel, Asher Chanan-Khan, Gregory J. Ahmann, Angela Dispenzieri, Kevin M Morrison, Marta Chesi, Morie A. Gertz, Noweeda Mirza, Yi Lin, Meaghen E. Sharik, Sikander Ailawadhi, Victoria M. Garbitt, Francis K. Buadi, Arianna Calcinotto, Daniel L. Riggs, Amylou C. Dueck, Ilseyar Akhmetzyanova, David Dingli, Martha Q. Lacy, Rafael Fonseca, Shaji Kumar, A. Keith Stewart, David R. Fooksman, Heidi E. Kosiorek, Niamh Keane |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male medicine.medical_treatment Gene Expression Antineoplastic Agents Mice Transgenic Biology General Biochemistry Genetics and Molecular Biology Article Inhibitor of Apoptosis Proteins 03 medical and health sciences Mice Cancer immunotherapy Downregulation and upregulation Phagocytosis In vivo Interferon Cell Line Tumor medicine Animals Humans Cyclophosphamide Multiple myeloma Aged Aged 80 and over Macrophages General Medicine Dendritic Cells Middle Aged medicine.disease Disease Models Animal Thiazoles 030104 developmental biology Apoptosis Cancer cell Immunology Interferon Type I Cancer research Tumor necrosis factor alpha Female Neoplasm Recurrence Local Multiple Myeloma medicine.drug |
| Popis: | The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-κB pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|